MedTrace Logo

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

NCT06259552 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2024-09-24

No results posted yet for this study

Summary

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

Conditions

Interventions

BIOLOGICAL

SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody

SPX- 303 Injection

Sponsors & Collaborators

  • SparX Biotech(Jiangsu) Co., Ltd.

    lead OTHER

Principal Investigators

  • Guidong Zhu · SparX Biotech

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-20
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06259552 on ClinicalTrials.gov